市場調查報告書
商品編碼
353899

黑色素瘤診斷及治療的全球市場:成長,趨勢,及預測

Melanoma Diagnostics and Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 114 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

 本報告提供全球黑色素瘤診斷及治療市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,產品類型·各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的假設
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭

第5章 市場區隔

  • 各產品類型
    • 診斷
    • 治療
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲地區
    • 南美

第6章 競爭情形

  • 企業簡介
    • Abbott Diagnostics
    • Amgen, Inc.
    • AstraZeneca PLC
    • Bayer AG
    • Bristol-Myers Squibb
    • 第一三共株式會社
    • F. Hoffman-La Roche Ltd.
    • GlaxoSmithKline PLC
    • Merck & Co., Inc
    • Novartis AG

第7章 市場機會及未來趨勢

目錄
Product Code: 55526

The melanoma diagnostics and therapeutics market is estimated to show good growth due to the increasing incidences of melanoma cases, rising governments initiatives for early detection and skin cancer treatment and rising technological advancements.

There has been a rapid increase in the melanoma cases that is found to be one of the major causes of morbidity and mortality in the US. Melanoma is one of the most common types of cancer in men and women. Among young adults, it is the second most common invasive cancer. According to WHO statistics, there are more than two million people that develops non-melanoma skin cancer, and around 132,000 people that develop melanoma. Therefore the rising number of cases of melanoma will eventually lead to the high CAGR for the melanoma diagnostics and therapeutics market.

Key Market Trends

Immune Therapy is Anticipated to be the Dominant in Therapeutics Segment during the Forecast Period

Immunotherapy is the use of medicines to stimulate a person immune system to recognize and destroy cancer cells effectively. There are several types of immunotherapies available that can be used to treat melanoma cancer.

Immunotherapy is found to hold the largest share that can be attributed to the effectiveness of drugs used in immunotherapy and an increase in their approvals. There are currently many FDA-approved immunotherapy options for melanoma that helps in the growth of the market. There have also many advances in using immunotherapy drugs known as checkpoint inhibitors to treat melanoma. Thus the strong emerging pipeline for melanoma treatment is expected to drive the immunotherapy segment over the forecast period.

North America Dominates the Melanoma Diagnostics and Therapeutics Market

North America holds a dominant share of the market owing to the rising incidence of melanoma and other skin cancers cases in the region. According to the Skin Cancer Foundation, one in every five Americans is likely to develop a kind of skin cancer during his/her lifetime. Furthermore, the American cancer society estimates 91,270 new cases of melanoma in the United States in 2018 alone. These statistics highlight the need for drugs that help in the management of melanoma over the coming years.

The United States government has also developed favorable reimbursement policies for treatment of melanoma diseases that is an attempt to fulfil unmet patient needs. This is expected to provide a healthy platform for growth to the North American market. Furthermore, the presence of numerous new players is expected to drive the overall market.

Competitive Landscape

The market is highly competitive in nature, with many key players involved in market expansion, partnerships, new product development, and R&D to increase market penetration. There are also several products are under clinical trials which are expected to receive approval and thus the market is likely to continue witnessing high competitive rivalry over the forecast period.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Burden of Melanoma Cases
    • 4.2.2 Rising Governments Initiatives for Early Detection and Skin Cancer Treatment
    • 4.2.3 Rising Technological Advancements
  • 4.3 Market Restraints
    • 4.3.1 High Cost Associated with the Therapy
    • 4.3.2 Stringent Regulatory Policies
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 By Diagnostics
      • 5.1.1.1 Dermatoscopy Devices
      • 5.1.1.2 Biopsy Devices
    • 5.1.2 By Therapeutics
      • 5.1.2.1 Chemotherapy
      • 5.1.2.2 Biological Therapy
      • 5.1.2.3 Targeted Therapy
      • 5.1.2.4 Immune Therapy
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East and Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle East and Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Diagnostics
    • 6.1.2 Amgen, Inc.
    • 6.1.3 AstraZeneca PLC
    • 6.1.4 Bayer AG
    • 6.1.5 Bristol-Myers Squibb
    • 6.1.6 Daiichi Sankyo Company Limited
    • 6.1.7 F. Hoffman-La Roche Ltd.
    • 6.1.8 GlaxoSmithKline PLC
    • 6.1.9 Merck & Co., Inc
    • 6.1.10 Novartis AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS